登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次现金管理受托方：中国工商银行股份有限公司厦门海沧支行（以下 简称"工商银行"）。 币结构性存款产品专户型2024年第310期Q款,365天。 ● 履行的审议程序：北京万泰生物药业股份有限公司（以下简称"公司"） 于2024年1月15日召开第五届董事会第二十五次会议、第五届监事会第二十五次会议，审议通过了《关 于使用部分闲置募集资金进行现金管理的议案》，同意公司使用最高额度不超过人民币20亿元（含）的 暂时闲置非公开发行股票募集资金适时投资安全性高、流动性好的保本型产品，单项产品期限最长不超 过12个月。该额度自公司董事会审议通过之日起12个月内有效，可由公司及全资子公司共同循环滚动使 用。具体内容详见公司于指定信息披露媒体披露的《北京万泰生物药业股份有限公司关于使用部分闲置 募集资金进行现金管理的公告》（公告编号：2024-005）。 公司于2025年1月14日召开第六届董事会第六次会议、第六届监事会第六次 ...

Trading Information Summary - On July 31, 2025, Wante Bio (603392) closed at 58.54 CNY, down 0.31%, with a turnover rate of 0.4% and a trading volume of 50,300 shares, amounting to a total transaction value of 296 million CNY [1] - On the same day, the fund flow for Wante Bio showed a net outflow of 538,100 CNY from institutional investors, accounting for 0.18% of the total transaction value, while retail investors had a net outflow of 1,267,360 CNY, representing 4.28% of the total transaction value [1][3] Company Announcement Summary - Wante Bio announced the redemption of 700 million CNY from a structured deposit product linked to the exchange rate, which was purchased from the Industrial and Commercial Bank of China [1] - The company held meetings on January 15, 2024, and January 14, 2025, to approve the use of idle fundraising for cash management, allowing for investments in safe and liquid principal-protected products, with a maximum investment limit of 2 billion CNY and 1.5 billion CNY for different fundraising sources [1] - As of the announcement date, Wante Bio had invested a total of 2,129.15 million CNY in financial management over the past twelve months, recovering 1,550 million CNY in principal and earning 38.19 million CNY in returns, with an outstanding principal amount of 579.15 million CNY [1]

本次现金管理受托方：中国工商银行股份有限公司厦门海沧支行（以下 简称"工商银行"）。 本次赎回金额：人民币70,000.00万元。 证券代码：603392 证券简称：万泰生物 公告编号：2025-038 北京万泰生物药业股份有限公司 关于使用部分闲置募集资金 进行现金管理到期赎回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司于2024年7月30日购买了中国工商银行挂钩汇率区间累计型法人人民币 结构性存款产品-专户型2024年第310期Q款理财产品70,000.00万元，该理财产品 已于2025年7月30日到期，截至本公告日，公司收回本金70,000.00万元，已于2025 年7月30日到账，收到产品收益1,823.50万元，已于2025年7月31日到账，并已划 至募集资金专用账户。 公司购买上述理财产品的具体情况详见公司于2024年7月30日在指定信息披 露媒体披露的《北京万泰生物药业股份有限公司关于使用部分闲置募集资金进行 现金管理到期赎回并继续进行现金管理的公告》（公告编号：2024-049） ...

Market Overview - A-shares opened mixed with the Shanghai Composite Index down 0.3% at 3604.7 points, the Shenzhen Component Index up 0.05% at 11208.46 points, and the ChiNext Index up 0.65% at 2382.97 points [1] - The total trading volume in the Shanghai and Shenzhen markets was 142.66 billion yuan [1] - CPO and PCB sectors saw significant gains, while military and non-ferrous metals sectors experienced declines [1] Company News - **Ningde Times** reported a revenue of 178.886 billion yuan for the first half of the year, a year-on-year increase of 7.27%, and a net profit of 30.512 billion yuan, up 33.02% year-on-year [2] - **Changjiang Power** approved a budget of approximately 26.6 billion yuan for the construction of the Gezhouba shipping capacity expansion project, with a total construction period of 91 months [2] - **Digital Certification** is undergoing a change in its controlling shareholder to Beijing Data Group, following a transfer of state-owned shares [3] - **Wantai Biological Pharmacy** launched a new PCR test kit for detecting Chikungunya virus, which is now widely used in blood supply institutions [3] - **Jia Yuan Technology** is advancing its ultra-thin copper foil project, aiming for an annual production capacity of 700,000 square meters by the end of 2026 [4] Industry Insights - The average interest rate for newly issued commercial personal housing loans in Q2 2025 was reported at 3.09% [5] - Domestic coal prices have been on the rise, with the price of 5500 kcal thermal coal at ports around 650 yuan per ton, an increase of 30 yuan from the end of June [8] - The Guangzhou Futures Exchange announced adjustments to trading limits for certain futures contracts, including industrial silicon and lithium carbonate [9] - The National Immigration Administration reported that over 300 million exit and entry documents were issued to Chinese citizens during the 14th Five-Year Plan period, with the number of valid ordinary passports exceeding 160 million [10]

Core Viewpoint - The company has successfully developed and launched a diagnostic kit for detecting Chikungunya virus, along with Zika and Dengue viruses, which is currently in widespread use in various blood collection agencies and research institutions in China [2]. Group 1 - The company has created a PCR-fluorescent probe method for the detection of Chikungunya virus [2]. - The diagnostic kit can accurately identify whether blood samples are infected with the Chikungunya virus [2]. - The product supports local healthcare systems in quickly identifying mosquito-borne diseases, facilitating precise prevention and control measures [2].

Core Viewpoint - Wantaibio has successfully developed and launched a PCR-fluorescent probe method test kit for Zika virus, dengue virus, and chikungunya virus, enabling precise identification of chikungunya virus infections in blood samples [1] Company Summary - The newly developed test kit is currently being widely used in multiple blood collection and supply institutions and research units across the country [1] - The product aids local medical and health systems in rapidly identifying mosquito-borne infectious diseases, facilitating precise prevention and control measures [1]

Core Viewpoint - Wanta Bio (603392.SH) has developed vaccine technology and successfully launched PCR-fluorescent probe test kits for Zika virus, dengue virus, and chikungunya virus, enabling precise identification of chikungunya virus infections in blood samples [1] Group 1 - The company possesses relevant vaccine development technology reserves [1] - The company has successfully developed and launched nucleic acid test kits for Zika virus, dengue virus, and chikungunya virus [1] - The test kits can accurately identify whether blood samples are infected with chikungunya virus [1]

Core Viewpoint - Wantaibio has successfully developed and launched a PCR-fluorescent probe method test kit for Zika virus, dengue virus, and chikungunya virus, which can accurately identify the presence of chikungunya virus in blood samples [1] Company Summary - The newly developed test kit is currently being widely used in various blood collection and supply institutions and research units across the country [1] - The product aids local medical and health systems in quickly identifying mosquito-borne infectious diseases, enabling precise prevention and control measures [1]

Market Overview - As of 14:00, the Shanghai Composite Index is at 3607.62 points, with a slight decline of -0.06% [1] - The total trading volume of A-shares today is 14,725.33 billion yuan [1] Technical Analysis - A total of 51 A-shares have seen their 5-day moving average cross below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - HaHuan (301137) with a distance of -1.61% - BaiLi Electric (600468) with a distance of -1.18% - JingYun (601908) with a distance of -0.92% [1] Individual Stock Performance - HaHuan (301137) is down by -1.34% with a trading turnover of 3.48% and a latest price of 33.85 yuan, which is -4.08% from the 10-day moving average [1] - BaiLi Electric (600468) has decreased by -1.50% with a turnover of 1.91% and a latest price of 6.56 yuan, -4.39% from the 10-day moving average [1] - JingYun (601908) has dropped by -2.33% with a turnover of 2.38% and a latest price of 3.77 yuan, -4.02% from the 10-day moving average [1] Additional Stock Data - Other stocks showing a downward trend include: - SiFang (605122) down -3.17% with a latest price of 14.37 yuan - HaoLaiKe (603898) down -3.78% with a latest price of 10.19 yuan - HeDuan Intelligent (603011) down -1.14% with a latest price of 15.65 yuan [1] - Stocks with minor declines include: - SuNeng (600925) down -0.39% with a latest price of 5.07 yuan - ChangSha Bank (601577) up 0.70% with a latest price of 10.10 yuan [1][2]

Core Viewpoint - WanTai Biologics has announced its first half-year loss forecast since its listing, expecting a net loss of 130 to 160 million yuan for the first half of the year, with a non-recurring loss of 230 to 260 million yuan, highlighting significant challenges in both its vaccine and IVD segments [2][10][12] Financial Performance - In 2023, WanTai's revenue plummeted by 50.73% to 5.511 billion yuan, and net profit dropped by 73.65% to 1.248 billion yuan, primarily due to increased competition and reduced demand for its HPV vaccines and COVID-19 testing [3][6] - For 2024, revenue and net profit are projected to decline further by 59.25% and 91.49%, respectively, with revenue at 2.245 billion yuan and a net loss of 186 million yuan [3][6] - The company recorded a historic first-quarter loss in 2025, with revenue of 401 million yuan, down 46.76%, and a net loss of approximately 52.78 million yuan [10] Business Segment Analysis - The vaccine segment, which previously contributed significantly to revenue, saw a dramatic decline in 2023, with a revenue drop of 84.69% and a reduction in gross margin by 21 percentage points [6][11] - The IVD segment, while experiencing slight growth of 4.91%, also faced a decline in gross margin to 64.97%, indicating a loss of its previous high-margin status [6][8] Market Dynamics - The approval of the nine-valent HPV vaccine "Xin Ke Ning 9" was initially seen as a potential turnaround for WanTai, but the stock price fell significantly post-approval, indicating market skepticism about the company's ability to recover [10][11] - The pricing strategy for the new vaccine, set at 499 yuan per dose, is aimed at increasing market accessibility but may compress profit margins and intensify competition with other companies entering the market [11][12] Inventory and Financial Health - By the end of 2024, WanTai's accounts receivable reached 2.243 billion yuan, nearly equal to its annual revenue, indicating potential cash flow issues [8] - The company also faced significant inventory challenges, with 31.37 million doses of vaccines in stock, leading to a provision for inventory write-downs of 252 million yuan [8]